

Abstract 616: Blood-based molecular landscapes of resistance to EGFR blockade in colorectal cancer patients

Giulia Siravegna; Benedetta Mussolin; Michela Buscarino; Giorgio Corti; Andrea Cassingena; Giovanni Crisafulli; Ryan B. Corcoran; Agostino Ponzetti; Alfredo Budillon; Patrizia Racca; Silvia Marsoni; Federica Di Nicolantonio; Fotios Loupakis; Salvatore Siena; Andrea Sartore Bianchi; Alberto Bardelli




+ [Author & Article Information](#)

Cancer Res (2015) 75 (15_Supplement): 616.

<https://doi.org/10.1158/1538-7445.AM2015-616>

 Split-Screen

 Share 


 Tools 

 Versions 

Abstract

The molecular landscape of colorectal cancers (CRC) is presently assessed by genotyping neoplastic tissue obtained through surgical or bioptic procedures. We evaluated whether blood-based molecular profiles could be used to perform diagnostic determinations and monitor resistance to therapy in colorectal cancer patients. We find that RAS pathway mutations, which are commonly evaluated prior to administration of anti-EGFR antibodies, can be ascertained directly in the blood. Sequencing of circulating DNA identified genomic alterations in KRAS, NRAS, MET, ERBB2, FLT3, and MEK1 in patients with primary or acquired resistance to cetuximab or panitumumab. Secondary resistance to EGFR blockade is frequently accompanied by emergence of mutant RAS clones, which can be tracked in blood. We find that upon withdrawal of anti-EGFR antibodies, KRAS alleles decline in circulating DNA indicating that clonal evolution continues beyond clinical progression. Functional analysis of CRC cell populations, which had acquired resistance to cetuximab, revealed that KRAS mutant clones can decay when EGFR blockade is suspended. These results establish proof of principle that genotyping colorectal cancers using circulating DNA can inform therapeutic decisions, identify mechanisms of drug resistance and provide insights for further lines of therapy.

Citation Format: Giulia Siravegna, Benedetta Mussolin, Michela Buscarino, Giorgio Corti, Andrea Cassingena, Giovanni Crisafulli, Ryan B. Corcoran, Agostino Ponzetti, Alfredo Budillon, Patrizia Racca, Silvia Marsoni, Federica Di Nicolantonio, Fotios Loupakis, Salvatore Siena, Andrea Sartore Bianchi, Alberto Bardelli. Blood-based molecular landscapes of resistance to EGFR blockade in colorectal cancer patients. [abstract]. In: Proceedings of the 106th Annual Meeting of the American Association for Cancer Research; 2015 Apr 18-22; Philadelphia, PA. Philadelphia (PA): AACR; Cancer Res 2015;75(15 Suppl):Abstract nr 616. doi:10.1158/1538-7445.AM2015-616



AAGR American Association
for Cancer Research[®] 2309046W



View Metrics

Citing Articles Via

Google Scholar

Email Alerts

Article Activity Alert

eTOC Alert

Breaking

Changes at the Top for Dana-Farber

BRAF–MEK Inhibitor Combo OK'd in Europe for NSCLC

New Restrictions on Tobacco Sales to Start in
September

[View more recent articles](#) 

Latest News

With Vorasidenib, Glioma Treatment Continues Evolving

Cancer Research on The Ballot: Moonshot and the
Future of Oncology Priorities

Massive Pathology Dataset Powers New AI Diagnostic
Tool

[View more recent articles](#) 

Research Watch

PIK3CA Mutations and Metabolic Conditions Drive
Clonal Expansion in Normal Esophagus

Macrophages Scavenge Myelin to Support Glioblastoma
Metabolism

Personalized Adoptive Cell Transfer Shows Promise in
Metastatic Colorectal Cancer

[View more recent articles](#) 

Issues

Online First

Collections

News

Twitter

Online ISSN 1538-7445 Print ISSN 0008-5472

AACR Journals


Blood Cancer Discovery	Cancer Prevention Research
Cancer Discovery	Cancer Research
Cancer Epidemiology, Biomarkers & Prevention	Cancer Research Communications
Cancer Immunology Research	Clinical Cancer Research
	Molecular Cancer Research
	Molecular Cancer Therapeutics

AACR American Association
for Cancer Research™



[Information on Advertising & Reprints](#)

[Information for Institutions/Librarians](#)

 [RSS Feeds](#)

[Privacy Policy](#)

Copyright © 2023 by the American Association for Cancer Research.